Research, Fundamental

Biopharma: The CAR-T Party is Getting Crowded

Stewart Glickman, CFA, Deputy Director of Research
28 July 2022


CAR-T cell therapy is a type of treatment for certain blood cancers that involves modifying a patient's T-cells in a lab by adding a gene for a chimeric antigen receptor (CAR). This enables the modified T-cells to attach to a specific cancer cell antigen and work to eliminate the cancer. CAR-T cell therapy is typically used after other cancer treatments have failed and may require multiple modified T-cells.

Want to learn more? Download the Report.


Fundamental Equity Research
Gain a comprehensive view of global themes, industries, and companies.
Public Policy Research
Identify opportunity and risks driven by public policy.
Forensic Accounting Research
Understand implications of public company financial reporting.